Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CALML3 | P27482 | 6/20 | 0.39 |
| ▸ | MAOA | P21397 | 8/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393910 | 0.88 | MAOA (0.51) | CYP2C19CYP3A4CALML3MAOAMAOB | |
| SCHEMBL1393833 | 0.88 | MAOA (0.51) | CYP2C19CYP3A4CALML3MAOAMAOB | |
| SCHEMBL1394408 | 0.83 | MC5R (0.42) | CALML3 | |
| SCHEMBL1394058 | 0.79 | CYP2C19 (0.41) | CYP2C19CYP3A4CALML3MAOAMAOB | |
| SCHEMBL18402977 | 0.78 | MAOA (0.35) | CYP2C19CYP3A4CALML3MAOAMAOB | |
| SCHEMBL1394717 | 0.78 | CALML3 (0.45) | CYP2C19CYP3A4CALML3MAOAMAOB | |
| SCHEMBL1393881 | 0.76 | CALML3 (0.41) | CYP2C19CYP3A4CALML3MAOAMAOB | |
| SCHEMBL1393629 | 0.76 | CALML3 (0.51) | CYP2C19CYP3A4CALML3MAOAMAOB | |
| SCHEMBL1393289 | 0.76 | CALML3 (0.43) | CYP2C19CYP3A4CALML3MAOAMAOB | |
| SCHEMBL1394027 | 0.75 | CALML3 (0.45) | CYP2C19CYP3A4CALML3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3217974-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | Melinta Therapeutics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016077818-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA THERAPEUTICS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7148219-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2006-11-23 | — | — | US | disclosed |
| US-6969726-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-11-29 | — | — | US | disclosed |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-09-15 | — | — | US | disclosed |
| US-20050043317-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CYP2C19 1321/4885CYP3A4 793/4885CALML3 3842/4885 |
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | CYP2C19 1321/4885CYP3A4 793/4885CALML3 3842/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CYP2C19 1321/4885CYP3A4 793/4885CALML3 3842/4885 |
| US-20050043317-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | CYP2C19 1321/4885CYP3A4 793/4885CALML3 3842/4885 |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CYP2C19 1321/4885CYP3A4 793/4885CALML3 3842/4885 |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | CYP2C19 1321/4885CYP3A4 793/4885CALML3 3842/4885 |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | PCNA, AADAC, MIF | CYP2C19 1321/4885CYP3A4 793/4885CALML3 3842/4885 |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | CYP2C19 1321/4885CYP3A4 793/4885CALML3 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.